CONCISE ORIGINAL REPORT
Precision medicine, agriculture, and genome editing: science and ethics
Carlos G. Moscoso,
Kelly R. Potz,
Shaoyuan Tan,
Pamala A. Jacobson,
Kavita M. Berger,
Clifford J. Steer,
Corresponding Author
Carlos G. Moscoso
Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota
Address for correspondence: Carlos G. Moscoso, M.D., Ph.D. and Clifford J. Steer, M.D., Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Minnesota Medical School, Phillips-Wangensteen Building, 516 Delaware Street, S.E., Minneapolis, MN 55455. [email protected]; [email protected]Search for more papers by this authorKelly R. Potz
College of Pharmacy, University of Minnesota, Minneapolis, Minnesota
Search for more papers by this authorShaoyuan Tan
Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Saint Paul, Minnesota
Search for more papers by this authorPamala A. Jacobson
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota
Search for more papers by this authorCorresponding Author
Clifford J. Steer
Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota
Department of Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, Minnesota
Address for correspondence: Carlos G. Moscoso, M.D., Ph.D. and Clifford J. Steer, M.D., Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Minnesota Medical School, Phillips-Wangensteen Building, 516 Delaware Street, S.E., Minneapolis, MN 55455. [email protected]; [email protected]Search for more papers by this author
Carlos G. Moscoso,
Kelly R. Potz,
Shaoyuan Tan,
Pamala A. Jacobson,
Kavita M. Berger,
Clifford J. Steer,
Corresponding Author
Carlos G. Moscoso
Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota
Address for correspondence: Carlos G. Moscoso, M.D., Ph.D. and Clifford J. Steer, M.D., Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Minnesota Medical School, Phillips-Wangensteen Building, 516 Delaware Street, S.E., Minneapolis, MN 55455. [email protected]; [email protected]Search for more papers by this authorKelly R. Potz
College of Pharmacy, University of Minnesota, Minneapolis, Minnesota
Search for more papers by this authorShaoyuan Tan
Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Saint Paul, Minnesota
Search for more papers by this authorPamala A. Jacobson
Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota
Search for more papers by this authorCorresponding Author
Clifford J. Steer
Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota
Department of Genetics, Cell Biology and Development, University of Minnesota Medical School, Minneapolis, Minnesota
Address for correspondence: Carlos G. Moscoso, M.D., Ph.D. and Clifford J. Steer, M.D., Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Minnesota Medical School, Phillips-Wangensteen Building, 516 Delaware Street, S.E., Minneapolis, MN 55455. [email protected]; [email protected]Search for more papers by this authorThis article is dedicated to the memory of Dr. Michael P. Murtaugh, a pioneering driver and invaluable force for the iCOMOS series of conferences.
Abstract
The era of precision medicine has generated advances in various fields of science and medicine with the potential for a paradigm shift in healthcare delivery that will ultimately lead to an individualized approach to medicine. Such timely topics were explored in 2018 at a workshop held at the Third International Conference on One Medicine One Science (iCOMOS), in Minneapolis, Minnesota. A broad range of scientists and regulatory experts provided detailed insights into the challenges and opportunities associated with precision medicine and gene editing. There was a general consensus that advances in studying the genomic traits driving differential pharmacogenomics will undoubtedly enhance individualized treatments for a wide variety of diseases. Ethical considerations, societal implications, approaches for prioritizing safe and secure use of treatment modalities, and the advent of high-throughput computing and analysis of large, complex datasets were discussed. Large biobanks, such as the All of Us Research Program and the Veterans Affairs Million Veterans Program, can aid studies of various conditions in massive cohorts of patients. As the applications of precision medicine continue to mature, the full potential and promise of these individualized approaches will continue to yield important advances in transplant medicine, oncology, public health, agriculture, pharmacology, and bioinformatics.
References
- 1Collins, F.S. & H. Varmus. 2015. A new initiative on precision medicine. N. Engl. J. Med. 372: 793–795.
- 2Feero, W.G., C.A. Wicklund & D. Veenstra. 2018. Precision medicine, genome sequencing, and improved population health. JAMA 319: 1979–1980.
- 3Mirnezami, R., J. Nicholson & A. Darzi. 2012. Preparing for precision medicine. N. Engl. J. Med. 366: 489–491.
- 4 Food and Agriculture Organization of the United Nations. 2016. FAOSTAT database. Rome, Italy: FAO.
- 5Ma, X., Q. Zhu, Y. Chen & Y.G. Liu. 2016. CRISPR/cas9 platforms for genome editing in plants: developments and applications. Mol. Plant 9: 961–974.
- 6Jansen, R., J.D. Embden, W. Gaastra & L.M. Schouls. 2002. Identification of genes that are associated with DNA repeats in prokaryotes. Mol. Microbiol. 43: 1565–1575.
- 7Mojica, F.J., C. Díez-Villaseñor, J. García-Martínez & E. Soria. 2005. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J. Mol. Evol. 60: 174–182.
- 8Jinek, M., K. Chylinski, I. Fonfara, et al. 2012. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 337: 816–821.
- 9Bortesi, L. & R. Fischer. 2015. The CRISPR/Cas9 system for plant genome editing and beyond. Biotechnol. Adv. 33: 41–52.
- 10Demorest, Z.L., A. Coffman, N.J. Baltes, et al. 2016. Direct stacking of sequence-specific nuclease-induced mutations to produce high oleic and low linolenic soybean oil. BMC Plant Biol. 16: 225.
- 11Taylor, N., P. Chavarriaga, K. Raemakers, et al. 2004. Development and application of transgenic technologies in cassava. Plant Mol. Biol. 56: 671–688.
- 12Hummel, A.W., R.D. Chauhan, T. Cermak, et al. 2018. Allele exchange at the EPSPS locus confers glyphosate tolerance in cassava. Plant Biotechnol. J. 16: 1275–1282.
- 13Schönbrunn, E., S. Eschenburg, W.A. Shuttleworth, et al. 2001. Interaction of the herbicide glyphosate with its target enzyme 5-enolpyruvylshikimate 3-phosphate synthase in atomic detail. Proc. Natl. Acad. Sci. USA 98: 1376–1380.
- 14Mustalahti, K., C. Catassi, A. Reunanen, et al. 2010. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann. Med. 42: 587–595.
- 15Sapone, A., K.M. Lammers, V. Casolaro, et al. 2011. Divergence of gut permeability and mucosal immune gene expression in two gluten-associated conditions: celiac disease and gluten sensitivity. BMC Med. 9: 23.
- 16Ozuna, C.V., J.C. Iehisa, M.J. Giménez, et al. 2015. Diversification of the celiac disease α-gliadin complex in wheat: a 33-mer peptide with six overlapping epitopes, evolved following polyploidization. Plant J. 82: 794–805.
- 17Sánchez-León, S., J. Gil-Humanes, C.V. Ozuna, et al. 2018. Low-gluten, nontransgenic wheat engineered with CRISPR/Cas9. Plant Biotechnol. J. 16: 902–910.
- 18Lorant, A., S. Pedersen, I. Holst, et al. 2017. The potential role of genetic assimilation during maize domestication. PLoS One 12: e0184202.
- 19Mauricio, R. 2001. Mapping quantitative trait loci in plants: uses and caveats for evolutionary biology. Nat. Rev. Genet. 2: 370–381.
- 20Zsögön, A., T. Cermak, D. Voytas & L.E. Peres. 2017. Genome editing as a tool to achieve the crop ideotype and de novo domestication of wild relatives: case study in tomato. Plant Sci. 256: 120–130.
- 21Von Staden, H. 1989. Herophilus: the Art of Medicine in Early Alexandria: Edition, Translation, and Essays. Cambridge, NY: Cambridge University Press.
- 22Maehle, A.H.T.U. 1987. Animal Experimentation from Antiquity to the End of the Eighteenth Century: Attitudes and Arguments. London: Croom Helm.
- 23Katz, J.N., S.B. Waters, I.B. Hollis & P.P. Chang. 2015. Advanced therapies for end-stage heart failure. Curr. Cardiol. Rev. 11: 63–72.
- 24Mozaffarian, D., E.J. Benjamin, A.S. Go, et al. 2016. Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133: e38–e360.
- 25Swindle, M.M., A. Makin, A.J. Herron, et al. 2012. Swine as models in biomedical research and toxicology testing. Vet. Pathol. 49: 344–356.
- 26Hart, E.A., M. Caccamo, J.L. Harrow, et al. 2007. Lessons learned from the initial sequencing of the pig genome: comparative analysis of an 8 Mb region of pig chromosome 17. Genome Biol. 8: R168.
- 27Reardon, S. 2015. New life for pig-to-human transplants. Nature 527: 152–154.
- 28Ibrahim, Z., J. Busch, M. Awwad, et al. 2006. Selected physiologic compatibilities and incompatibilities between human and porcine organ systems. Xenotransplantation 13: 488–499.
- 29Längin, M., T. Mayr, B. Reichart, et al. 2018. Consistent success in life-supporting porcine cardiac xenotransplantation. Nature 564: 430–433.
- 30Brauch, K.M., M.L. Karst, K.J. Herron, et al. 2009. Mutations in ribonucleic acid binding protein gene cause familial dilated cardiomyopathy. J. Am. Coll. Cardiol. 54: 930–941.
- 31Levit, L.A., E.S. Kim, B.L. McAneny, et al. 2019. Implementing precision medicine in community-based oncology programs: three models. J. Oncol. Pract. 15: 325–329.
- 32Long, G.V., A. Hauschild, M. Santinami, et al. 2017. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377: 1813–1823.
- 33Soria, J.C., Y. Ohe, J. Vansteenkiste, et al. 2018. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378: 113–125.
- 34Slamon, D.J., B. Leyland-Jones, S. Shak, et al. 2001. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344: 783–792.
- 35Harris, M.H., S.G. DuBois, J.L. Glade Bender, et al. 2016. Multicenter feasibility study of tumor molecular profiling to inform therapeutic decisions in advanced pediatric solid tumors: the Individualized Cancer Therapy (iCat) Study. JAMA Oncol. 2: 608–615.
- 36Ivics, Z., Z. Izsvak, A. Minter & P.B. Hackett. 1996. Identification of functional domains and evolution of Tc1-like transposable elements. Proc. Natl. Acad. Sci. USA 93: 5008–5013.
- 37Carlson, C.M. & D.A. Largaespada. 2005. Insertional mutagenesis in mice: new perspectives and tools. Nat. Rev. Genet. 6: 568–580.
- 38Jacob, H.J., J. Lazar, M.R. Dwinell, et al. 2010. Gene targeting in the rat: advances and opportunities. Trends Genet. 26: 510–518.
- 39Dupuy, A.J., L.M. Rogers, J. Kim, et al. 2009. A modified Sleeping Beauty transposon system that can be used to model a wide variety of human cancers in mice. Cancer Res. 69: 8150–8156.
- 40Jung, S., S.W. Ro, G. Jung, et al. 2013. Sleeping Beauty transposon system harboring HRAS, c-Myc and shp53 induces sarcomatoid carcinomas in mouse skin. Oncol. Rep. 29: 1293–1298.
- 41Kodama, T., J. Yi, J.Y. Newberg, et al. 2018. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Proc. Natl. Acad. Sci. USA 115: E10417–E10426.
- 42Evans, E.E., A.S. Jonason, H. Bussler, et al. 2015. Antibody blockade of Semaphorin 4D promotes immune infiltration into tumor and enhances response to other immunomodulatory therapies. Cancer Immunol. Res. 3: 689–701.
- 43Plouffe, S.W., Z. Meng, K.C. Lin, et al. 2016. Characterization of Hippo pathway components by gene inactivation. Mol. Cell 64: 993–1008.
- 44Lamar, J.M., P. Stern, H. Liu, et al. 2012. The Hippo pathway target, YAP, promotes metastasis through its TEAD–interaction domain. Proc. Natl. Acad. Sci. USA 109: E2441–E2450.
- 45Pulley, J.M., J.C. Denny, J.F. Peterson, et al. 2012. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin. Pharmacol. Ther. 92: 87–95.
- 46Roden, D.M., J.M. Pulley, M.A. Basford, et al. 2008. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin. Pharmacol. Ther. 84: 362–369.
- 47Denny, J.C., M.D. Ritchie, M.A. Basford, et al. 2010. PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations. Bioinformatics 26: 1205–1210.
- 48Bush, W.S., M.T. Oetjens & D.C. Crawford. 2016. Unravelling the human genome–phenome relationship using phenome-wide association studies. Nat. Rev. Genet. 17: 129–145.
- 49Denny, J.C., L. Bastarache & D.M. Roden. 2016. Phenome-wide association studies as a tool to advance precision medicine. Annu. Rev. Genomics Hum. Genet. 17: 353–373.
- 50Roden, D.M. & J.C. Denny. 2016. Integrating electronic health record genotype and phenotype datasets to transform patient care. Clin. Pharmacol. Ther. 99: 298–305.
- 51Brem, R.B., G. Yvert, R. Clinton & L. Kruglyak. 2002. Genetic dissection of transcriptional regulation in budding yeast. Science 296: 752–755.
- 52GTEx Consortium . 2013. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 45: 580–585.
- 53Gamazon, E.R., H.E. Wheeler, K.P. Shah, et al. 2015. A gene-based association method for mapping traits using reference transcriptome data. Nat. Genet. 47: 1091–1098.
- 54Unlu, G., E.R. Gamazon, X. Qi, et al. 2019. GRIK5 genetically regulated expression associated with eye and vascular phenomes: discovery through iteration among biobanks, electronic health records, and zebrafish. Am. J. Hum. Genet. 104: 503–519.
- 55Pusapati, G.V., G. Luchetti & S.R. Pfeffer. 2012. Ric1–Rgp1 complex is a guanine nucleotide exchange factor for the late Golgi Rab6A GTPase and an effector of the medial Golgi Rab33B GTPase. J. Biol. Chem. 287: 42129–42137.
- 56Bastarache, L., J.J. Hughey, S. Hebbring, et al. 2018. Phenotype risk scores identify patients with unrecognized Mendelian disease patterns. Science 359: 1233–1239.
- 57Lander, E.S., L.M. Linton, B. Birren, et al. 2001. Initial sequencing and analysis of the human genome. Nature 409: 860–921.
- 58Venter, J.C., M.D. Adams, E.W. Myers, et al. 2001. The sequence of the human genome. Science 291: 1304–1351.
- 59Weinshilboum, R.M. & S.L. Sladek. 1980. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32: 651–662.
- 60Lennard, L., J.A. Van Loon & R.M. Weinshilboum. 1989. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46: 149–154.
- 61Mahgoub, A., J.R. Idle, L.G. Dring, et al. 1977. Polymorphic hydroxylation of Debrisoquine in man. Lancet 2: 584–586.
- 62Broly, F., A. Gaedigk, M. Heim, et al. 1991. Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 10: 545–558.
- 63Gorrod, J.W. 1978. Biological Oxidation of Nitrogen: Proceedings of the 2nd International Symposium on the Biological Oxidation of Nitrogen in Organic Molecules held at the Chelsea College, University of London, United Kingdom, 19–23 September, 1977. Amsterdam, New York: Elsevier/North-Holland Biomedical Press; sole distributors for the USA and Canada, Elsevier North-Holland.
- 64Gonzalez, F.J., R.C. Skoda, S. Kimura, et al. 1988. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442–446.
- 65Farrugia, G. & R.M. Weinshilboum. 2013. Challenges in implementing genomic medicine: the Mayo Clinic Center for Individualized Medicine. Clin. Pharmacol. Ther. 94: 204–206.
- 66 Surveillance, Epidemiology, and End Results (SEER). 2018. Program populations (1969–2017). Accessed on August 2, 2019. www.seer.cancer.gov/popdata. National Cancer Institute, DCCPS, Surveillance Research Program; released December 2018.
- 67Yu, J., B. Qin, A.M. Moyer, et al. 2017. Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. Breast Cancer Res. 19: 130.
- 68Yu, J., B. Qin, A.M. Moyer, et al. 2018. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J. Clin. Invest. 128: 2376–2388.
- 69Niedzwiecki, M.M., D.I. Walker, R. Vermeulen, et al. 2019. The Exposome: molecules to populations. Annu. Rev. Pharmacol. Toxicol. 59: 107–127.
- 70 Pew Research Center. 2018. Public views of gene editing for babies depend on how it would be used. Accessed September 21, 2019. https://www.pewresearch.org/science/2018/07/26/public-views-of-gene-editing-for-babies-depend-on-how-it-would-be-used/.
- 71Collins, F. 2019. Statement on NIH funding of research using gene-editing technologies in human embryos. Accessed August 2, 2019. https://www.nih.gov/about-nih/who-we-are/nih-director/statements/statement-nih-funding-research-using-gene-editing-technologies-human-embryos.
- 72Baltimore, D., P. Berg, M. Botchan, et al. 2015. Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science 348: 36–38.
- 73Lanphier, E., F. Urnov, S.E. Haecker, et al. 2015. Don't edit the human germ line. Nature 519: 410–411.
- 74Cohen, J. 2019. Inside the circle of trust. Science 365: 430–437.
- 75Cohen, J. 2019. The long shadow of a CRISPR scandal. Science 365: 436.
- 76 National Academy of Sciences, Engineering, and Medicine. 2017. Human Genome Editing: Science, Ethics, and Governance. Washington, DC: National Academies Press.
- 77Li, J.R., S. Walker, J.B. Nie & X.Q. Zhang. 2019. Experiments that led to the first gene-edited babies: the ethical failings and the urgent need for better governance. J. Zhejiang Univ. Sci. B 20: 32–38.
- 78Ryder, S.P. 2018. #CRISPRbabies: notes on a Scandal. CRISPR J. 1: 355–357.
- 79Liang, P., Y. Xu, X. Zhang, et al. 2015. CRISPR/cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 6: 363–372.
- 80 Kaiser Permanente Research Program on genes, environment, and health. Accessed August 2, 2019. https://divisionofresearch.kaiserpermanente.org/genetics/rpgeh.
- 81Elliott, P., T.C. Peakman & U.K. Biobank. 2008. The UK Biobank sample handling and storage protocol for the collection, processing and archiving of human blood and urine. Int. J. Epidemiol. 37: 234–244.
- 82Sudlow, C., J. Gallacher, N. Allen, et al. 2015. UK Biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 12: e1001779.
- 83Chen, Z., J. Chen, R. Collins, et al. 2011. China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-up. Int. J. Epidemiol. 40: 1652–1666.
- 84Gaziano, J.M., J. Concato, M. Brophy, et al. 2016. Million Veteran Program: a mega-biobank to study genetic influences on health and disease. J. Clin. Epidemiol. 70: 214–223.
- 85Gelernter, J., N. Sun, R. Polimanti, et al. 2019. Genome-wide association study of post-traumatic stress disorder reexperiencing symptoms in >165,000 U.S. veterans. Nat. Neurosci. 22: 1394–1401.
Citing Literature
